Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.05.14.594200Source: DataRank Database

The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2024). On theSindex it has a DataRank of 0.104. It has been cited 1 time.

N/A

0.104DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: greenTopics (50)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.104

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (6)

Rana Abdelnabi ORCID,Bernadett Boda ORCID,Samuel Constant ORCID,Johan Neyts ORCID,Dirk Jochmans ORCID

Live enrichment

PubMed:38798406 OpenAlex:https://openalex.org/W4396975634

European Commission

Grant: 101003627

Swift COronavirus therapeutics REsponse

European Commission

Grant: 812673

Organoids for Virus Research - An innovative training-ETN programme

European Commission

Grant: 101005077

Corona Accelerated R&D in Europe

National Institutes of Health

Grant: 5R01AI177512-03

Development of an Oral Pan-Coronavirus Drug Cocktail

NIAID NIH HHS

Grant: R01 AI177512

greenLicense: cc-by-nc-nd

repositoryhttps://doi.org/10.1101/2024.05.14.594200

publisherhttps://syndication.highwire.org/content/doi/10.1101/2024.05.14.594200

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38798406

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11118304

Fields of Study

Respiratory viral infections researchSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Keywords

RibavirinVirologyPotencyCoronavirusPandemicHamsterViral replicationVirusMedicineNasal administrationPharmacologyImmunologyBiologyCoronavirus disease 2019 (COVID-19)In vitroInternal medicineInfectious disease (medical specialty)Hepatitis C virusAdenosine3214 Pharmacology and pharmaceutical sciencesCytidineVirus ReplicationHydroxylaminesAntiviral AgentsArticleCoronavirus OC43, Human1108 Medical MicrobiologyCricetinaeAnimalsHumansPharmacology & PharmacyCells, CulturedScience & TechnologyAlanineMesocricetusSARS-CoV-2COVID-19Epithelial Cells3207 Medical microbiologyAdenosine MonophosphateCOVID-19 Drug Treatment3107 MicrobiologyDisease Models, AnimalDrug Therapy, Combination1115 Pharmacology and Pharmaceutical SciencesLife Sciences & Biomedicine0605 Microbiology

Sustainable Development Goals

SDG 0: Good health and well-being